Fruquintinib is a molecular targeted tumor drug independently developed by Hutchison Whampoa with complete intellectual property rights. It is a domestically produced drug that was first developed by Chinese local pharmaceutical companies, initiated clinical research in Chinese patients, and jointly developed by Chinese local researchers. At the same time, it is a major scientific and technological special project of the National 12th Five Year Plan for "Major New Drug Creation", which can be said to be 100% domestically produced.

Working principle

Existing anti VEGF drugs typically inhibit tumor angiogenesis by suppressing the VEGF-A/VEGFR-2 pathway, with limited inhibition of VEGFR-3 activation and tumor lymphangiogenesis induced by VEGF-C. Furquintinib has a potent and highly selective inhibitory effect on the three isoforms of VEGFR-1, 2, and 3, which can simultaneously inhibit tumor angiogenesis and lymphangiogenesis, laying the foundation for its potent anti-tumor effect.